WO2002062954A3 - Antisense modulation of casein kinase 2-beta expression - Google Patents

Antisense modulation of casein kinase 2-beta expression Download PDF

Info

Publication number
WO2002062954A3
WO2002062954A3 PCT/US2002/003159 US0203159W WO02062954A3 WO 2002062954 A3 WO2002062954 A3 WO 2002062954A3 US 0203159 W US0203159 W US 0203159W WO 02062954 A3 WO02062954 A3 WO 02062954A3
Authority
WO
WIPO (PCT)
Prior art keywords
casein kinase
beta
expression
antisense modulation
beta expression
Prior art date
Application number
PCT/US2002/003159
Other languages
French (fr)
Other versions
WO2002062954A2 (en
Inventor
Robert Mckay
Susan M Freier
Jacqueline R Wyatt
Original Assignee
Isis Pharmaceuticals Inc
Robert Mckay
Susan M Freier
Jacqueline R Wyatt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Robert Mckay, Susan M Freier, Jacqueline R Wyatt filed Critical Isis Pharmaceuticals Inc
Priority to AU2002247063A priority Critical patent/AU2002247063A1/en
Publication of WO2002062954A2 publication Critical patent/WO2002062954A2/en
Publication of WO2002062954A3 publication Critical patent/WO2002062954A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-beta. Methods of using these compounds for modulation of Casein kinase 2-beta expression and for treatment of diseases associated with expression of Casein kinase 2-beta are provided.
PCT/US2002/003159 2001-02-08 2002-01-31 Antisense modulation of casein kinase 2-beta expression WO2002062954A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002247063A AU2002247063A1 (en) 2001-02-08 2002-01-31 Antisense modulation of casein kinase 2-beta expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/780,175 2001-02-08
US09/780,175 US6440738B1 (en) 2001-02-08 2001-02-08 Antisense modulation of casein kinase 2-beta expression

Publications (2)

Publication Number Publication Date
WO2002062954A2 WO2002062954A2 (en) 2002-08-15
WO2002062954A3 true WO2002062954A3 (en) 2002-12-05

Family

ID=25118859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003159 WO2002062954A2 (en) 2001-02-08 2002-01-31 Antisense modulation of casein kinase 2-beta expression

Country Status (3)

Country Link
US (1) US6440738B1 (en)
AU (1) AU2002247063A1 (en)
WO (1) WO2002062954A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
DE10241111A1 (en) * 2002-09-03 2004-03-11 Ernst-Moritz-Arndt-Universität Modulation of insulin synthesis
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
FR2857013B1 (en) * 2003-07-02 2005-09-30 Commissariat Energie Atomique SMALL INTERFERING RNA SPECIFIC OF ALPHA, ALPHA PRIME AND BETA SUBUNITS OF PROTEIN KINASE CK2 AND THEIR APPLICATIONS
WO2005049832A2 (en) * 2003-11-14 2005-06-02 Yale University FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2006065724A2 (en) * 2004-12-14 2006-06-22 Regents Of The University Of Minnesota Casein kinase 2 antisense therapy
ES2397661T3 (en) 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
US20160230172A1 (en) * 2013-10-14 2016-08-11 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US10987308B2 (en) 2014-09-03 2021-04-27 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US20020035090A1 (en) * 2000-05-15 2002-03-21 Zeldis Jerome B. Compositions and methods for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US20020035090A1 (en) * 2000-05-15 2002-03-21 Zeldis Jerome B. Compositions and methods for the treatment of cancer

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRANCH, A.: "A good antisense molecule is hard to find", TIS, vol. 23, February 1998 (1998-02-01), pages 45 - 50, XP004108000 *
LOREN, P.: "Requirement of casein kinase 2 for entry into and progression through early phases of the cell cycle", CELLULAR AND MOLECULAR BIOLOGY RESEARCH, vol. 40, no. 5/6, 1994, pages 519 - 527, XP002951288 *
MINGZI, C.: "The beta subunit of CKII negatively regulates xenopus oocyte maturation", PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 9136 - 9140, XP002951286 *
PEPPERKOK, R.: "Cell growth stimulation by EGF: inhibition through antisense-oligodeoxynucleotides demonstrates important role of casein kinase II", EXPERIMENTAL CELL RESEARCH, vol. 197, 1991, pages 245 - 253, XP002952117 *
PYERIN, W.: "Early cell growth stimulation is inhibited by casein kinase II antisense oligodeoxynucleotides", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 660, 1992, pages 295 - 297, XP002951285 *
ULLOA, L.: "Depletion of catalytic and regulatory subunits of protein kinase CK2 by antisense oligonucleotide treatment of neuroblastoma cells", CELLULAR AND MOLECULAR NEUROBIOLOGY, vol. 14, no. 5, 1994, pages 407 - 414, XP002951287 *

Also Published As

Publication number Publication date
WO2002062954A2 (en) 2002-08-15
US6440738B1 (en) 2002-08-27
AU2002247063A1 (en) 2002-08-19

Similar Documents

Publication Publication Date Title
WO2002036743A3 (en) Antisense modulation of calreticulin expression
WO2003011887A3 (en) Antisense modulation of apolipoprotein b expression
WO2002092772A3 (en) Antisense modulation of ptp1b expression
WO2004011610A3 (en) Antisense modulation of polo-like kinase expression
WO2002010378A3 (en) Antisense modulation of ptp1b expression
WO2003010284A3 (en) Antisense modulation of c-reactive protein expression
WO2003022222A3 (en) Antisense modulation of protein kinase r expression
WO2003046132A3 (en) Antisense modulation of myd88 expression
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
WO2003054154A3 (en) Antisense modulation of mucin 1, transmembrane expression
WO2003018600A3 (en) Antisense modulation of microsomal triglyceride transfer protein expression
EP1224202A4 (en) Antisense modulation of integrin-linked kinase expression
WO2003053341A3 (en) Antisense modulation of ship-1 expression
WO2002062954A3 (en) Antisense modulation of casein kinase 2-beta expression
WO2002095053A3 (en) Antisense modulation of src-c expression
WO2002062951A3 (en) Antisense modulation of casein kinase 2-alpha prime expression
WO2002062818A3 (en) Antisense modulation of casein kinase 2-alpha expression
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2003052062A3 (en) Antisense modulation of cd36l1 expression
WO2002036810A3 (en) Antisense modulation of talin expression
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2003027229A3 (en) Antisense modulation of rip2 expression
WO2003040161A3 (en) Antisense modulation of activating transcription factor 3 expression
EP1248635A4 (en) Antisense modulation of glycogen synthase kinase 3 alpha expression
WO2003031576A3 (en) Antisense modulation of inhibitor-kappa b kinase-gamma expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP